Incyte | INCY - Current Assets


Incyte reported $5.52B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Agenus USD 78.81M 16.47M Jun/2026
Agios Pharmaceuticals USD 752.1M 34.43M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amgen USD 34.36B 598M Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Exelixis USD 1.32B 70.8M Sep/2026
Gilead Sciences USD 16.55B 4.02B Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
MacroGenics USD 295.08M 26.61M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Moderna USD 7.34B 1.53B Sep/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Novartis USD 28.75B 1.4B Sep/2026
Novartis USD 28.75B 2.14B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026